Acarix to apply for listing on Nasdaq First North Premier

Acarix AB (publ) (”Acarix” or ”the Company”), a Swedish/Danish commercial stage medical device company, specializing in non-invasive, non-radiation acoustic rule-out of Coronary Artery Disease (CAD), announced on November 16, 2016, that it has decided to apply for for a listing of the company’s shares on Nasdaq First North Premier in Stockholm (the “IPO”). In connection with the IPO, the company intends to raise approximately SEK 140 million, an amount that is already fully secured through subscription undertakings and guarantee commitments. The funds raised will primarily be used to execute the company’s commercialization strategy and anticipated launch in Q2, 2017, with initial focus on Germany, UK, Sweden and Denmark for the already CE‑marked CADScor®System.

 

Press Releases

November 24, 2016
Acarix offentliggör prospekt avseende erbjudande till allmänheten av bolagets aktier inför notering på Nasdaq First North Premier

November 16, 2016
Acarix to apply for listing on Nasdaq First North Premier

 

Prospectus and Teaser

 

Company Overview and Analysis

 

Summary of the Offering

Offer Price: SEK 17,60 per Share
Application period for the general public: November 28 – December 7, 2016.
First day of trading in the Shares: On or around December 19, 2016.
Settlement date: December 14, 2016.

 

Contact

For further information, please contact:

Christian Lindholm
CFO / Investor Relations
Telephone: +46 705 118 333
Email: secli@acarix.com